nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Fingolimod—multiple sclerosis	0.164	0.804	CbGbCtD
Methylnaltrexone—CYP2D6—Dexamethasone—multiple sclerosis	0.04	0.196	CbGbCtD
Methylnaltrexone—Naloxone—TLR4—multiple sclerosis	0.0274	0.889	CrCbGaD
Methylnaltrexone—Redness—Cladribine—multiple sclerosis	0.0236	0.0556	CcSEcCtD
Methylnaltrexone—Injection site reaction—Cladribine—multiple sclerosis	0.0158	0.0373	CcSEcCtD
Methylnaltrexone—Stinging—Prednisolone—multiple sclerosis	0.0106	0.025	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.0104	0.0245	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Fingolimod—multiple sclerosis	0.00984	0.0232	CcSEcCtD
Methylnaltrexone—Stinging—Triamcinolone—multiple sclerosis	0.00976	0.023	CcSEcCtD
Methylnaltrexone—Skin disorder—Fingolimod—multiple sclerosis	0.00975	0.023	CcSEcCtD
Methylnaltrexone—Stinging—Betamethasone—multiple sclerosis	0.00885	0.0209	CcSEcCtD
Methylnaltrexone—Stinging—Dexamethasone—multiple sclerosis	0.00885	0.0209	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00866	0.0204	CcSEcCtD
Methylnaltrexone—Erythema—Cladribine—multiple sclerosis	0.00697	0.0164	CcSEcCtD
Methylnaltrexone—Flatulence—Cladribine—multiple sclerosis	0.00687	0.0162	CcSEcCtD
Methylnaltrexone—Diarrhoea—Fingolimod—multiple sclerosis	0.00686	0.0162	CcSEcCtD
Methylnaltrexone—Dizziness—Fingolimod—multiple sclerosis	0.00663	0.0156	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00589	0.0139	CcSEcCtD
Methylnaltrexone—Oedema—Cladribine—multiple sclerosis	0.00569	0.0134	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Cladribine—multiple sclerosis	0.00558	0.0131	CcSEcCtD
Methylnaltrexone—Skin disorder—Cladribine—multiple sclerosis	0.00552	0.013	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Cladribine—multiple sclerosis	0.0055	0.013	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00491	0.0116	CcSEcCtD
Methylnaltrexone—Pain—Cladribine—multiple sclerosis	0.00486	0.0115	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.00479	0.0113	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Cladribine—multiple sclerosis	0.00465	0.011	CcSEcCtD
Methylnaltrexone—Erythema—Mitoxantrone—multiple sclerosis	0.00458	0.0108	CcSEcCtD
Methylnaltrexone—Abdominal pain—Cladribine—multiple sclerosis	0.0045	0.0106	CcSEcCtD
Methylnaltrexone—Skin disorder—Azathioprine—multiple sclerosis	0.00449	0.0106	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00399	0.00941	CcSEcCtD
Methylnaltrexone—Diarrhoea—Cladribine—multiple sclerosis	0.00389	0.00917	CcSEcCtD
Methylnaltrexone—OPRM1—nerve—multiple sclerosis	0.00382	0.236	CbGeAlD
Methylnaltrexone—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.00378	0.00891	CcSEcCtD
Methylnaltrexone—Dizziness—Cladribine—multiple sclerosis	0.00376	0.00886	CcSEcCtD
Methylnaltrexone—Erythema—Prednisolone—multiple sclerosis	0.00376	0.00885	CcSEcCtD
Methylnaltrexone—Oedema—Mitoxantrone—multiple sclerosis	0.00374	0.00881	CcSEcCtD
Methylnaltrexone—Abdominal pain—Azathioprine—multiple sclerosis	0.00366	0.00861	CcSEcCtD
Methylnaltrexone—Skin disorder—Mitoxantrone—multiple sclerosis	0.00363	0.00855	CcSEcCtD
Methylnaltrexone—Vomiting—Cladribine—multiple sclerosis	0.00362	0.00852	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.00361	0.00851	CcSEcCtD
Methylnaltrexone—Erythema—Triamcinolone—multiple sclerosis	0.00346	0.00814	CcSEcCtD
Methylnaltrexone—Erythema—Methylprednisolone—multiple sclerosis	0.00345	0.00812	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—multiple sclerosis	0.00342	0.111	CrCbGaD
Methylnaltrexone—Nausea—Cladribine—multiple sclerosis	0.00338	0.00796	CcSEcCtD
Methylnaltrexone—Pain—Mitoxantrone—multiple sclerosis	0.0032	0.00753	CcSEcCtD
Methylnaltrexone—Diarrhoea—Azathioprine—multiple sclerosis	0.00316	0.00745	CcSEcCtD
Methylnaltrexone—Erythema—Betamethasone—multiple sclerosis	0.00314	0.00739	CcSEcCtD
Methylnaltrexone—Erythema—Dexamethasone—multiple sclerosis	0.00314	0.00739	CcSEcCtD
Methylnaltrexone—Oedema—Prednisolone—multiple sclerosis	0.00307	0.00722	CcSEcCtD
Methylnaltrexone—Dizziness—Azathioprine—multiple sclerosis	0.00306	0.0072	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00306	0.0072	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisolone—multiple sclerosis	0.00297	0.00698	CcSEcCtD
Methylnaltrexone—Abdominal pain—Mitoxantrone—multiple sclerosis	0.00296	0.00696	CcSEcCtD
Methylnaltrexone—Vomiting—Azathioprine—multiple sclerosis	0.00294	0.00693	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.00292	0.00687	CcSEcCtD
Methylnaltrexone—Oedema—Triamcinolone—multiple sclerosis	0.00282	0.00664	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00276	0.0065	CcSEcCtD
Methylnaltrexone—Nausea—Azathioprine—multiple sclerosis	0.00275	0.00647	CcSEcCtD
Methylnaltrexone—Skin disorder—Methylprednisolone—multiple sclerosis	0.00273	0.00644	CcSEcCtD
Methylnaltrexone—Erythema—Prednisone—multiple sclerosis	0.00273	0.00643	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.00273	0.00642	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.00272	0.00641	CcSEcCtD
Methylnaltrexone—Pain—Prednisolone—multiple sclerosis	0.00262	0.00618	CcSEcCtD
Methylnaltrexone—Oedema—Dexamethasone—multiple sclerosis	0.00256	0.00603	CcSEcCtD
Methylnaltrexone—Oedema—Betamethasone—multiple sclerosis	0.00256	0.00603	CcSEcCtD
Methylnaltrexone—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00256	0.00603	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Betamethasone—multiple sclerosis	0.00251	0.00591	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Dexamethasone—multiple sclerosis	0.00251	0.00591	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Betamethasone—multiple sclerosis	0.00247	0.00583	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.00247	0.00583	CcSEcCtD
Methylnaltrexone—Pain—Triamcinolone—multiple sclerosis	0.00241	0.00568	CcSEcCtD
Methylnaltrexone—Vomiting—Mitoxantrone—multiple sclerosis	0.00238	0.0056	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.00231	0.00544	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.0023	0.00542	CcSEcCtD
Methylnaltrexone—Erythema—Methotrexate—multiple sclerosis	0.00228	0.00538	CcSEcCtD
Methylnaltrexone—Oedema—Prednisone—multiple sclerosis	0.00223	0.00525	CcSEcCtD
Methylnaltrexone—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00222	0.00524	CcSEcCtD
Methylnaltrexone—Nausea—Mitoxantrone—multiple sclerosis	0.00222	0.00523	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00221	0.0052	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00221	0.0052	CcSEcCtD
Methylnaltrexone—Pain—Dexamethasone—multiple sclerosis	0.00219	0.00516	CcSEcCtD
Methylnaltrexone—Pain—Betamethasone—multiple sclerosis	0.00219	0.00516	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Prednisone—multiple sclerosis	0.00219	0.00515	CcSEcCtD
Methylnaltrexone—Skin disorder—Prednisone—multiple sclerosis	0.00216	0.0051	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisone—multiple sclerosis	0.00215	0.00508	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.00209	0.00493	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.00209	0.00493	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisolone—multiple sclerosis	0.00203	0.00478	CcSEcCtD
Methylnaltrexone—Abdominal pain—Betamethasone—multiple sclerosis	0.00202	0.00477	CcSEcCtD
Methylnaltrexone—Abdominal pain—Dexamethasone—multiple sclerosis	0.00202	0.00477	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00193	0.00455	CcSEcCtD
Methylnaltrexone—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00193	0.00454	CcSEcCtD
Methylnaltrexone—Dizziness—Triamcinolone—multiple sclerosis	0.00187	0.00439	CcSEcCtD
Methylnaltrexone—Dizziness—Methylprednisolone—multiple sclerosis	0.00186	0.00438	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.00184	0.00567	CbGpPWpGaD
Methylnaltrexone—Nervous system disorder—Methotrexate—multiple sclerosis	0.00183	0.0043	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00182	0.00429	CcSEcCtD
Methylnaltrexone—Nausea—Prednisolone—multiple sclerosis	0.00182	0.00429	CcSEcCtD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—CCR5—multiple sclerosis	0.00182	0.00562	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.00181	0.00559	CbGpPWpGaD
Methylnaltrexone—Skin disorder—Methotrexate—multiple sclerosis	0.00181	0.00426	CcSEcCtD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—FAS—multiple sclerosis	0.00181	0.00557	CbGpPWpGaD
Methylnaltrexone—Hyperhidrosis—Methotrexate—multiple sclerosis	0.0018	0.00424	CcSEcCtD
Methylnaltrexone—Vomiting—Triamcinolone—multiple sclerosis	0.00179	0.00422	CcSEcCtD
Methylnaltrexone—Vomiting—Methylprednisolone—multiple sclerosis	0.00179	0.00422	CcSEcCtD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	0.00177	0.00546	CbGpPWpGaD
Methylnaltrexone—Abdominal pain—Prednisone—multiple sclerosis	0.00176	0.00415	CcSEcCtD
Methylnaltrexone—Diarrhoea—Dexamethasone—multiple sclerosis	0.00175	0.00412	CcSEcCtD
Methylnaltrexone—Diarrhoea—Betamethasone—multiple sclerosis	0.00175	0.00412	CcSEcCtD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCL3—multiple sclerosis	0.00172	0.0053	CbGpPWpGaD
Methylnaltrexone—Dizziness—Betamethasone—multiple sclerosis	0.00169	0.00399	CcSEcCtD
Methylnaltrexone—Dizziness—Dexamethasone—multiple sclerosis	0.00169	0.00399	CcSEcCtD
Methylnaltrexone—Nausea—Triamcinolone—multiple sclerosis	0.00168	0.00395	CcSEcCtD
Methylnaltrexone—Nausea—Methylprednisolone—multiple sclerosis	0.00167	0.00394	CcSEcCtD
Methylnaltrexone—OPRM1—GPCR ligand binding—S1PR1—multiple sclerosis	0.00167	0.00515	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.00167	0.00514	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.00167	0.00514	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00164	0.00507	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00164	0.00507	CbGpPWpGaD
Methylnaltrexone—OPRM1—brainstem—multiple sclerosis	0.00164	0.101	CbGeAlD
Methylnaltrexone—Vomiting—Betamethasone—multiple sclerosis	0.00163	0.00383	CcSEcCtD
Methylnaltrexone—Vomiting—Dexamethasone—multiple sclerosis	0.00163	0.00383	CcSEcCtD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.00162	0.00499	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.00162	0.00499	CbGpPWpGaD
Methylnaltrexone—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00161	0.00379	CcSEcCtD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCR3—multiple sclerosis	0.0016	0.00493	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCR3—multiple sclerosis	0.0016	0.00492	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—GPR65—multiple sclerosis	0.00159	0.00492	CbGpPWpGaD
Methylnaltrexone—Pain—Methotrexate—multiple sclerosis	0.00159	0.00375	CcSEcCtD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCR2—multiple sclerosis	0.00155	0.00479	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CCR2—multiple sclerosis	0.00155	0.00479	CbGpPWpGaD
Methylnaltrexone—OPRM1—Opioid Signalling—POMC—multiple sclerosis	0.00155	0.00478	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.00153	0.00473	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.00153	0.00471	CbGpPWpGaD
Methylnaltrexone—Diarrhoea—Prednisone—multiple sclerosis	0.00152	0.00359	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.00152	0.00359	CcSEcCtD
Methylnaltrexone—Nausea—Dexamethasone—multiple sclerosis	0.00152	0.00358	CcSEcCtD
Methylnaltrexone—Nausea—Betamethasone—multiple sclerosis	0.00152	0.00358	CcSEcCtD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.00148	0.00456	CbGpPWpGaD
Methylnaltrexone—Dizziness—Prednisone—multiple sclerosis	0.00147	0.00347	CcSEcCtD
Methylnaltrexone—Abdominal pain—Methotrexate—multiple sclerosis	0.00147	0.00347	CcSEcCtD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCL13—multiple sclerosis	0.00146	0.0045	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCR1—multiple sclerosis	0.00146	0.0045	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.00144	0.00444	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CNR1—multiple sclerosis	0.00143	0.00442	CbGpPWpGaD
Methylnaltrexone—Vomiting—Prednisone—multiple sclerosis	0.00142	0.00334	CcSEcCtD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.00136	0.00421	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCR3—multiple sclerosis	0.00135	0.00416	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—GPR65—multiple sclerosis	0.00135	0.00415	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.00133	0.0041	CbGpPWpGaD
Methylnaltrexone—Nausea—Prednisone—multiple sclerosis	0.00132	0.00312	CcSEcCtD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.00132	0.00406	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.00131	0.00405	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CCR2—multiple sclerosis	0.00131	0.00404	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.0013	0.00399	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CXCL10—multiple sclerosis	0.00129	0.00398	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CXCL10—multiple sclerosis	0.00129	0.00398	CbGpPWpGaD
Methylnaltrexone—Diarrhoea—Methotrexate—multiple sclerosis	0.00127	0.003	CcSEcCtD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.00127	0.00391	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.00125	0.00386	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.00123	0.0038	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCL13—multiple sclerosis	0.00123	0.0038	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCR1—multiple sclerosis	0.00123	0.0038	CbGpPWpGaD
Methylnaltrexone—Dizziness—Methotrexate—multiple sclerosis	0.00123	0.0029	CcSEcCtD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.00122	0.00375	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CNR1—multiple sclerosis	0.00121	0.00373	CbGpPWpGaD
Methylnaltrexone—OPRK1—nervous system—multiple sclerosis	0.00121	0.0745	CbGeAlD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.00119	0.00366	CbGpPWpGaD
Methylnaltrexone—Vomiting—Methotrexate—multiple sclerosis	0.00118	0.00279	CcSEcCtD
Methylnaltrexone—OPRK1—central nervous system—multiple sclerosis	0.00116	0.0717	CbGeAlD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.00115	0.00356	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—CD4—multiple sclerosis	0.00114	0.00353	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.00114	0.00351	CbGpPWpGaD
Methylnaltrexone—OPRK1—cerebellum—multiple sclerosis	0.00114	0.0701	CbGeAlD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.00112	0.00346	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—S1PR1—multiple sclerosis	0.00112	0.00345	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCL5—multiple sclerosis	0.00111	0.00343	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CCL5—multiple sclerosis	0.00111	0.00342	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.00111	0.00342	CbGpPWpGaD
Methylnaltrexone—Nausea—Methotrexate—multiple sclerosis	0.00111	0.00261	CcSEcCtD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CXCL10—multiple sclerosis	0.00109	0.00336	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.00107	0.00331	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—IL1B—multiple sclerosis	0.00106	0.00326	CbGpPWpGaD
Methylnaltrexone—OPRM1—midbrain—multiple sclerosis	0.00104	0.0644	CbGeAlD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.00104	0.00322	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCL3—multiple sclerosis	0.00104	0.0032	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.00103	0.00316	CbGpPWpGaD
Methylnaltrexone—OPRM1—spinal cord—multiple sclerosis	0.00102	0.0629	CbGeAlD
Methylnaltrexone—OPRK1—Signaling by GPCR—S1PR1—multiple sclerosis	0.00101	0.00313	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCR5—multiple sclerosis	0.001	0.00309	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—PTGER4—multiple sclerosis	0.001	0.00308	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—CCR5—multiple sclerosis	0.001	0.00308	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCR3—multiple sclerosis	0.000966	0.00298	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000962	0.00297	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—RGS1—multiple sclerosis	0.00095	0.00293	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000944	0.00291	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCR2—multiple sclerosis	0.000939	0.0029	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CCL5—multiple sclerosis	0.000938	0.00289	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000928	0.00286	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000926	0.00286	CbGpPWpGaD
Methylnaltrexone—OPRK1—brain—multiple sclerosis	0.000922	0.0569	CbGeAlD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000906	0.00279	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GPR65—multiple sclerosis	0.000901	0.00278	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000882	0.00272	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL3—multiple sclerosis	0.000878	0.00271	CbGpPWpGaD
Methylnaltrexone—OPRM1—Opioid Signalling—MAPK1—multiple sclerosis	0.000876	0.0027	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.00087	0.00268	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CNR1—multiple sclerosis	0.000867	0.00267	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000866	0.00267	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—RGS1—multiple sclerosis	0.000863	0.00266	CbGpPWpGaD
Methylnaltrexone—OPRM1—nervous system—multiple sclerosis	0.000858	0.053	CbGeAlD
Methylnaltrexone—OPRM1—Signaling by GPCR—S1PR1—multiple sclerosis	0.000858	0.00265	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—PTGER4—multiple sclerosis	0.000845	0.00261	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—CCR5—multiple sclerosis	0.000845	0.00261	CbGpPWpGaD
Methylnaltrexone—OPRM1—central nervous system—multiple sclerosis	0.000826	0.051	CbGeAlD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCR1—multiple sclerosis	0.000824	0.00254	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000824	0.00254	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—TGFB1—multiple sclerosis	0.000821	0.00253	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GPR65—multiple sclerosis	0.000818	0.00252	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCR3—multiple sclerosis	0.000816	0.00252	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—MAPK1—multiple sclerosis	0.000805	0.00248	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—RGS1—multiple sclerosis	0.000803	0.00248	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000795	0.00245	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCR2—multiple sclerosis	0.000794	0.00245	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LINGO1—multiple sclerosis	0.000791	0.00244	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000784	0.00242	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—POMC—multiple sclerosis	0.000783	0.00241	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—POMC—multiple sclerosis	0.000781	0.00241	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CXCL10—multiple sclerosis	0.000781	0.00241	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—CCL2—multiple sclerosis	0.000766	0.00236	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GPR65—multiple sclerosis	0.000761	0.00235	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000748	0.00231	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCR1—multiple sclerosis	0.000748	0.00231	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000746	0.0023	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CNR1—multiple sclerosis	0.000733	0.00226	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—RGS1—multiple sclerosis	0.000729	0.00225	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000706	0.00218	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCR1—multiple sclerosis	0.000696	0.00215	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000696	0.00215	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GPR65—multiple sclerosis	0.000691	0.00213	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TAGAP—multiple sclerosis	0.000686	0.00212	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCL5—multiple sclerosis	0.000672	0.00207	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000672	0.00207	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LINGO1—multiple sclerosis	0.000669	0.00206	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—POMC—multiple sclerosis	0.00066	0.00204	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CXCL10—multiple sclerosis	0.00066	0.00203	CbGpPWpGaD
Methylnaltrexone—CYP2D6—brainstem—multiple sclerosis	0.000657	0.0405	CbGeAlD
Methylnaltrexone—OPRM1—brain—multiple sclerosis	0.000656	0.0405	CbGeAlD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR1—multiple sclerosis	0.000632	0.00195	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000632	0.00195	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000621	0.00192	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—IL6—multiple sclerosis	0.000618	0.00191	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000608	0.00187	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCR5—multiple sclerosis	0.000605	0.00187	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—S1PR1—multiple sclerosis	0.0006	0.00185	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GPC5—multiple sclerosis	0.000583	0.0018	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TAGAP—multiple sclerosis	0.00058	0.00179	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL5—multiple sclerosis	0.000568	0.00175	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000565	0.00174	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000546	0.00168	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL3—multiple sclerosis	0.000533	0.00164	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCR2—multiple sclerosis	0.000531	0.00164	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	0.000525	0.00162	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	0.000514	0.00158	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PTGER4—multiple sclerosis	0.000513	0.00158	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCR5—multiple sclerosis	0.000512	0.00158	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RGS1—multiple sclerosis	0.00051	0.00157	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—S1PR1—multiple sclerosis	0.000507	0.00156	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCR3—multiple sclerosis	0.000496	0.00153	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GPC5—multiple sclerosis	0.000493	0.00152	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CNR1—multiple sclerosis	0.00049	0.00151	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GPR65—multiple sclerosis	0.000483	0.00149	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCR2—multiple sclerosis	0.000482	0.00149	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000478	0.00147	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—POMC—multiple sclerosis	0.000473	0.00146	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—CCL2—multiple sclerosis	0.000463	0.00143	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000461	0.00142	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL3—multiple sclerosis	0.000451	0.00139	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCR2—multiple sclerosis	0.000449	0.00138	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CNR1—multiple sclerosis	0.000445	0.00137	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL13—multiple sclerosis	0.000442	0.00136	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR1—multiple sclerosis	0.000442	0.00136	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000441	0.00136	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PTGER4—multiple sclerosis	0.000434	0.00134	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RGS1—multiple sclerosis	0.000431	0.00133	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCR3—multiple sclerosis	0.000419	0.00129	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CNR1—multiple sclerosis	0.000414	0.00128	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GPR65—multiple sclerosis	0.000408	0.00126	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR2—multiple sclerosis	0.000407	0.00126	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SRM—multiple sclerosis	0.000404	0.00125	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CXCL10—multiple sclerosis	0.000401	0.00124	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—POMC—multiple sclerosis	0.0004	0.00123	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—CCL2—multiple sclerosis	0.000391	0.00121	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCL5—multiple sclerosis	0.00038	0.00117	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CNR1—multiple sclerosis	0.000376	0.00116	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—POMC—multiple sclerosis	0.000375	0.00116	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL13—multiple sclerosis	0.000374	0.00115	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR1—multiple sclerosis	0.000374	0.00115	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000373	0.00115	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL5—multiple sclerosis	0.000345	0.00106	CbGpPWpGaD
Methylnaltrexone—CYP2D6—nervous system—multiple sclerosis	0.000344	0.0212	CbGeAlD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCR5—multiple sclerosis	0.000342	0.00106	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CXCL10—multiple sclerosis	0.000339	0.00104	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000337	0.00104	CbGpPWpGaD
Methylnaltrexone—CYP2D6—central nervous system—multiple sclerosis	0.000331	0.0204	CbGeAlD
Methylnaltrexone—CYP2D6—cerebellum—multiple sclerosis	0.000324	0.02	CbGeAlD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCL5—multiple sclerosis	0.000321	0.00099	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL3—multiple sclerosis	0.000315	0.000971	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCR5—multiple sclerosis	0.000311	0.000958	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL2RA—multiple sclerosis	0.000306	0.000944	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTGER4—multiple sclerosis	0.000303	0.000935	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PGR—multiple sclerosis	0.000299	0.000921	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCR3—multiple sclerosis	0.000293	0.000903	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL5—multiple sclerosis	0.000291	0.000899	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CD28—multiple sclerosis	0.00029	0.000894	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCR5—multiple sclerosis	0.000289	0.000892	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	0.000285	0.000879	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	0.000285	0.000879	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	0.000285	0.000879	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR2—multiple sclerosis	0.000285	0.000878	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—POMC—multiple sclerosis	0.000267	0.000825	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL3—multiple sclerosis	0.000266	0.000821	CbGpPWpGaD
Methylnaltrexone—CYP2D6—brain—multiple sclerosis	0.000263	0.0162	CbGeAlD
Methylnaltrexone—OPRK1—Signaling Pathways—CNR1—multiple sclerosis	0.000263	0.000811	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR5—multiple sclerosis	0.000263	0.00081	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPC5—multiple sclerosis	0.000261	0.000804	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2RA—multiple sclerosis	0.000259	0.000798	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTGER4—multiple sclerosis	0.000256	0.00079	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PGR—multiple sclerosis	0.000252	0.000778	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCR3—multiple sclerosis	0.000247	0.000763	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CD28—multiple sclerosis	0.000245	0.000756	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—POMC—multiple sclerosis	0.000243	0.000749	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR2—multiple sclerosis	0.000241	0.000742	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL2—multiple sclerosis	0.000238	0.000733	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CXCL10—multiple sclerosis	0.000237	0.00073	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—POMC—multiple sclerosis	0.000226	0.000697	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CNR1—multiple sclerosis	0.000222	0.000685	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—RRM1—multiple sclerosis	0.000216	0.000666	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—TYK2—multiple sclerosis	0.000216	0.000665	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CD86—multiple sclerosis	0.000207	0.000638	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—POMC—multiple sclerosis	0.000205	0.000633	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL5—multiple sclerosis	0.000204	0.000628	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL2—multiple sclerosis	0.000201	0.000619	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CXCL10—multiple sclerosis	0.0002	0.000617	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—IL2—multiple sclerosis	0.000198	0.00061	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SPP1—multiple sclerosis	0.000189	0.000582	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR5—multiple sclerosis	0.000184	0.000566	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—TYK2—multiple sclerosis	0.000182	0.000562	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2RA—multiple sclerosis	0.000181	0.000558	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL2—multiple sclerosis	0.00018	0.000554	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CD86—multiple sclerosis	0.000175	0.000539	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL5—multiple sclerosis	0.000172	0.000531	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—IL2—multiple sclerosis	0.000167	0.000515	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOE—multiple sclerosis	0.000167	0.000515	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SPP1—multiple sclerosis	0.000159	0.000492	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR5—multiple sclerosis	0.000155	0.000478	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2RA—multiple sclerosis	0.000153	0.000471	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL2—multiple sclerosis	0.000152	0.000468	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CD80—multiple sclerosis	0.000151	0.000466	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—POMC—multiple sclerosis	0.000143	0.000442	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOE—multiple sclerosis	0.000141	0.000435	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL2—multiple sclerosis	0.00014	0.000433	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MAPK1—multiple sclerosis	0.000137	0.000423	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CD80—multiple sclerosis	0.000128	0.000393	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TYK2—multiple sclerosis	0.000127	0.000393	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—BCHE—multiple sclerosis	0.000124	0.000382	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—POMC—multiple sclerosis	0.000121	0.000374	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL2—multiple sclerosis	0.000119	0.000366	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MAPK1—multiple sclerosis	0.000116	0.000358	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TYK2—multiple sclerosis	0.000108	0.000332	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL2—multiple sclerosis	0.000106	0.000327	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—multiple sclerosis	0.000106	0.000325	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—multiple sclerosis	0.0001	0.000309	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL2—multiple sclerosis	8.96e-05	0.000276	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—STAT3—multiple sclerosis	8.92e-05	0.000275	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—multiple sclerosis	8.92e-05	0.000275	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—multiple sclerosis	8.48e-05	0.000262	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MYC—multiple sclerosis	8.29e-05	0.000256	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFB1—multiple sclerosis	8.27e-05	0.000255	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MAPK1—multiple sclerosis	8.11e-05	0.00025	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—STAT3—multiple sclerosis	7.54e-05	0.000233	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOE—multiple sclerosis	7.46e-05	0.00023	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MYC—multiple sclerosis	7.01e-05	0.000216	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFB1—multiple sclerosis	6.99e-05	0.000216	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MAPK1—multiple sclerosis	6.86e-05	0.000211	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—POMC—multiple sclerosis	6.41e-05	0.000198	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—multiple sclerosis	6.23e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—multiple sclerosis	5.84e-05	0.00018	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—multiple sclerosis	5.27e-05	0.000162	CbGpPWpGaD
